Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

152 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population.
Crinò L, Bidoli P, Delmonte A, Grossi F, De Marinis F, Ardizzoni A, Vitiello F, Lo Russo G, Parra HS, Cortesi E, Cappuzzo F, Calabrò L, Tiseo M, Turci D, Gamucci T, Antonelli P, Morabito A, Chella A, Giannarelli D, Galetta D. Crinò L, et al. Among authors: gamucci t. Oncologist. 2019 Nov;24(11):e1165-e1171. doi: 10.1634/theoncologist.2018-0737. Epub 2019 Apr 17. Oncologist. 2019. PMID: 30996007 Free PMC article.
Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group.
Ardizzoni A, Hansen H, Dombernowsky P, Gamucci T, Kaplan S, Postmus P, Giaccone G, Schaefer B, Wanders J, Verweij J. Ardizzoni A, et al. Among authors: gamucci t. J Clin Oncol. 1997 May;15(5):2090-6. doi: 10.1200/JCO.1997.15.5.2090. J Clin Oncol. 1997. PMID: 9164222 Clinical Trial.
Prolonged gemcitabine infusion in advanced non-small cell lung carcinoma: a randomized phase II study of two different schedules in combination with cisplatin.
Ceribelli A, Gridelli C, De Marinis F, Fabi A, Gamucci T, Cortesi E, Barduagni M, Antimi M, Maione P, Migliorino MR, Giannarelli D, Cognetti F. Ceribelli A, et al. Among authors: gamucci t. Cancer. 2003 Jul 15;98(2):337-43. doi: 10.1002/cncr.11501. Cancer. 2003. PMID: 12872354 Free article. Clinical Trial.
Combined therapy with weekly irinotecan, infusional 5-fluorouracil and the selective COX-2 inhibitor rofecoxib is a safe and effective second-line treatment in metastatic colorectal cancer.
Gasparini G, Gattuso D, Morabito A, Longo R, Torino F, Sarmiento R, Vitale S, Gamucci T, Mariani L. Gasparini G, et al. Among authors: gamucci t. Oncologist. 2005 Oct;10(9):710-7. doi: 10.1634/theoncologist.10-9-710. Oncologist. 2005. PMID: 16249351 Free article. Clinical Trial.
Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study.
Gridelli C, Gallo C, Ceribelli A, Gebbia V, Gamucci T, Ciardiello F, Carozza F, Favaretto A, Daniele B, Galetta D, Barbera S, Rosetti F, Rossi A, Maione P, Cognetti F, Testa A, Di Maio M, Morabito A, Perrone F; GECO investigators. Gridelli C, et al. Among authors: gamucci t. Lancet Oncol. 2007 Jun;8(6):500-12. doi: 10.1016/S1470-2045(07)70146-8. Lancet Oncol. 2007. PMID: 17513173 Clinical Trial.
152 results